Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03307993 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
A Phase 1 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03307993 is a Phase 1 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 3 participants.
The verdict
NCT03307993, a Phase 1 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)
Interventions
- DRUG Idalopirdine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-09-22 |
| Est. Completion | 2018-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03307993
The ClinicalTrials.gov registry entry for NCT03307993 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idalopirdine is the first listed.
NCT03307993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03307993 about?
NCT03307993 is a clinical study titled "Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease". To investigate the brain receptor occupancy of idalopirdine in patients with Alzheimer's disease (AD)
What is the current status of trial NCT03307993?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-09-22. Estimated completion is 2018-02-19.
What interventions are being tested in trial NCT03307993?
The interventions under investigation include: Idalopirdine (DRUG).
Who is sponsoring clinical trial NCT03307993?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.